TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07608770: A Phase 2b, Randomized, Placebo-Controlled Study With Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat (Stage 1)

Sponsor: Caliway Biopharmaceuticals Co., Ltd. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 250 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07608770 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07608770 Rescue Dossier →